Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark OfficeBusiness Wire • 01/24/23
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue ResultsBusiness Wire • 01/06/23
Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/04/23
Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun PharmaceuticalsBusiness Wire • 01/03/23
Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus NephritisBusiness Wire • 11/30/22
Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational ResultsBusiness Wire • 11/03/22
Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022Business Wire • 10/28/22
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022Business Wire • 10/27/22
Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022Business Wire • 09/20/22
Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus NephritisBusiness Wire • 09/19/22
Aurinia Pharmaceuticals Inc's (AUPH) CEO Peter Greenleaf on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational ResultsBusiness Wire • 08/04/22